Five things for pharma marketers to know: Monday, December 5, 2016

1. The FDA approved Boehringer Ingelheim and Eli Lilly's Jardiance for a new indication to reduce cardiovascular death in adults with type 2 diabetes and cardiovascular disease. It's the first time that data has found that a diabetes drug can reduce the risk of cardiovascular disease. (Reuters)

2. Novartis said 82% of patients with acute lymphoblastic leukemia were disease-free three months after undergoing treatment with its experimental CAR-T therapy CTL019. The drugmaker tested the treatment on 50 children and adults with the blood cancer who did not respond to other treatment. (Reuters)

3. Physicians have reported serious risks associated with immunotherapy drugs, which are widely considered to be breakthrough cancer treatments. Doctors say that immunotherapies are the cause of new diabetes in 17 patients. (NYT)

4. An executive hired to work on Apple's health initiatives reportedly left the company. Yoky Matsuoka worked on key projects like the HealthKit software and CareKit and was a co-founder of Google X, which produces Google Glass. (Bloomberg)

5. A federal jury said Johnson & Johnson must pay more than $1 billion to six plaintiffs who received the company's Pinnacle hip implants. The plaintiffs said the implants' design caused tissue death and bone erosion. (NYT)